Accelerating Drug Discovery for FTD RFP

The Accelerating Drug Discovery for FTD RFP supports frontotemporal degeneration drug discovery through a joint ADDF-AFTD route. It sits within ADDF's broader Alzheimer's and dementia funding platform but is focused on FTD rather than Alzheimer's disease alone. The program uses grant funding, is annual, and is open globally to for-profit companies, nonprofits, universities, and research organizations. Individuals are not eligible. The record gives a median award of $300,000, which suggests a compact funding line aimed at targeted work rather than very large programs. The index also places it among ADDF's co-funded calls and frames the full proposal stage as invitation-only. The strongest applicants are teams with an FTD project that can justify nonprofit capital. Biotech companies in particular need to show a clear need for philanthropic funding, which keeps the route aimed at work that is scientifically promising but not yet a clean fit for standard commercial financing. That makes it useful for early translational work, especially where an outside partner can de-risk the next step.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.